Jane Street
PLX icon

Jane Street’s Protalix BioTherapeutics PLX Stock Holding History

Jane Street’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.8K Buy
+31,700
New +$78.7K ﹤0.01% 10832
2025
Q4 		– Sell
-36,500
Closed -$81K – 12093
2025
Q3 		$81K Buy
+36,500
New +$59.4K ﹤0.01% 10221
2021
Q4 		– Sell
-104,700
Closed -$139K – 10653
2021
Q3 		$139K Sell
104,700
-107,400
-51% -$163K ﹤0.01% 9106
2021
Q2 		$405K Buy
212,100
+193,000
+1,010% +$664K ﹤0.01% 7639
2021
Q1 		$85K Buy
+19,100
New +$88.9K ﹤0.01% 8693

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jane Street's PLX Position: Q1 2026 in Review

Jane Street reduced its Protalix BioTherapeutics (PLX) stake by 94% in Q1 2026, selling an estimated $676K and leaving 17,342 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #11060.

Jane Street first reported a position in PLX in Q2 2013 and has held it in 47 quarters since. The position peaked at $753K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Jane Street held 17,342 shares of Protalix BioTherapeutics worth $37.6K as of Q1 2026.
  • Jane Street sold 272,575 Protalix BioTherapeutics shares in Q1 2026, an estimated $676K.
  • Protalix BioTherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11060 holding.
  • Jane Street first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 47 quarters since.
  • Jane Street's Protalix BioTherapeutics position peaked at $753K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.